PhaseBio to Present Data on its Elastin-Like Polypeptide Biopolymer Technology Platform at the TIDES: Oligonucleotide & Peptide Therapeutics Conference

Malvern, PA, April 25, 2017 — PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing biopolymer-based drugs for the treatment of orphan diseases with an initial focus on cardiopulmonary disorders, today announced that Vice President of Research & Scientific Affairs Jim Ballance, Ph.D., will present preclinical and clinical data on the company’s proprietary elastin-like polypeptide (ELP) biopolymer technology platform in an oral session at the TIDES: Oligonucleotide & Peptide Therapeutics conference to be held April 30 – May 3 at the Manchester Grand Hyatt in San Diego, CA.

Details on the presentation are as follows:

Title: Elastin-Like Polypeptide Biopolymers Enhance the Pharmacology of Therapeutic Peptides

Track: Peptide Discovery, Preclinical and Clinical

Session: Peptides in the Clinic: Lessons Learned

Date / time: Tuesday, May 2, 3:05 – 3:30 p.m. PDT

Location: Cortez Hill

For additional information on the conference, please visit:

About PhaseBio

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company developing new and improved biotherapeutics for the treatment of orphan diseases, with a focus on cardiopulmonary disorders. The company’s proprietary technology platform uses recombinant elastin-like polypeptide (ELP) biopolymers to control the half-life, bioavailability and physical characteristics of molecules for ease of administration. The resulting compounds are engineered for a specific rate of absorption to enhance efficacy and reduce side effects, which can lead to less-frequent dosing and better patient compliance. PhaseBio’s lead development candidate, PB1046, is a first-in-class weekly vasoactive intestinal peptide (VIP) receptor agonist for the treatment of pulmonary arterial hypertension (PAH); the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) and X-linked dilated cardiomyopathy; and the treatment of cystic fibrosis. PhaseBio is privately owned, with headquarters and research laboratories in Malvern, PA. For more information, please visit


Media Contact:
Laura Bagby, 6 Degrees
(312) 448-8098